Approved on August 7, 2020, oliceridine (Olinvyk) is intended for patients who have not found relief with other treatments.

TauRx Pharmaceuticals Ltd has revealed the filing of a Marketing Authorisation Application in the UK for hydromethylthionine mesylate (HMTM).

risdiplam FDA approval on August 7, 2020, has provided new hope and convenience for individuals affected by SMA.

Formycon AG, together with their licensing partner Klinge Biopharma GmbH, has disclosed that the FYB203/AHZANTIVE (aflibercept-mrbb), a biosimilar to Eylea, has received approval from the U.S. Food and Drug Administration.

tafasitamab FDA approval on July 31, 2020, provides hope for patients with limited treatment options, though ongoing studies are necessary to fully understand its long-term efficacy and safety.

Ubix Therapeutics and Yuhan unveil an exclusive licensing deal for UBX-103, an oral AR degrader to treat metastatic castration-resistant prostate cancer.

Approved by the FDA on July 24, 2020, it utilizes innovative CAR-T cell technology to target and eliminate cancer cells, although it comes with significant risks and side effects that require careful management by healthcare professionals.

The European Union has approved the world's first Sanofi and Regenerant drug, dulprizumab, targeting IL-4Rα for COPD treatment.

on August 12, 2021, the FDA expanded its approval to include the treatment of idiopathic hypersomnia (IH) in adults.

Jul 4th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration (FDA) approved Inqovi on July 7, 2020, for the treatment of certain types of myelodysplastic syndromes (MDS).

Pierre Fabre Laboratories have received European marketing approval for OBGEMSA™ (vibegron) to treat overactive bladder.